In the first dose-escalation trial conducted by Younes et al., 45 patients with refractory or recurrent CD30-positive hematologic malignancies, including HL (n = 42), systemic anaplastic large cell lymphoma (sALCL; n = 2), and angioimmunoblastic T cell lymphoma (n = 1) were treated on an every 3 week basis [100]. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.